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http:WHAT THIS PAPER ADDS
The use of the transealing technique for embolization of type 2 endoleaks is described. The basis of the
technique is obliteration of the leak after gaining direct access to the aneurysm sac. Access is achieved by means
of an introducer sheath inserted between the stent-graft and the iliac artery wall, at the distal stent-graft landing
zone. This study shows that transealing is feasible and may represent an alternative to other percutaneous
treatments in selected cases.Objective: Type 2 endoleak (T2EL) is the Achilles’ heel of endovascular abdominal aortic aneurysm repair.
Experience with transealing, an alternative technique for the treatment of T2ELs, is described.
Methods: The outcome of a group of patients treated with transealing has been reviewed. Femoral access was
obtained with a 9-Fr sheath. A super-stiff guide wire and a stiff hydrophilic wire were placed inside the stent-graft
and a Piton GC catheter inserted. The stiff hydrophilic wire was retrieved to allow the catheter to regain its
curvature and the catheter tip was placed against the iliac wall, at the edge of the stent-graft. The hydrophilic
wire was then forced between the stent-graft and arterial wall into the sac. A 5/6-Fr introducer was inserted
inside the sac and angiography was performed to evaluate the leak. Coils, cyanoacrylate, or ﬁbrin glue were
deployed. After removal of the catheters, the iliac limb was ballooned.
Results: Seventeen patients were treated between February 2009 and April 2013. It was possible to access the
aneurysm in 16/17 attempts. One patient treated with acrylic glue suffered from colon ischemia. One
intraoperative secondary type 1b endoleak was treated with an iliac extension. Mean follow-up was 21.5 months.
Three months of follow-up were completed in 14 patients with a 53% freedom from endoleak rate. At 1 year, the
rate was 45%. During the study period, there was one surgical conversion, one aneurysm growth, and one re-
embolization procedure. The remaining leaks remained stable.
Conclusions: This study shows that transealing is feasible and represents a valid alternative in selected patients.
The advantages of this technique are mainly its low invasiveness, reduced costs, and ease of use.
 2014 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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Therapeutic embolizationINTRODUCTION
Type 2 endoleak (T2EL) remains the Achilles’ heel of
endovascular aortic aneurysm repair (EVAR) with an inci-
dence of up to 20%.1,2 These leaks, for the most part, have a
benign course, and approximately 90% resolve within 1 year
of the procedure.3,4
Therefore, the relevance of T2EL remains the subject of
debate, and most authors agree that treatment isresponding author. G. Coppi, Department of Vascular Surgery,
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//dx.doi.org/10.1016/j.ejvs.2014.01.013warranted only in the case of persistent leaks (i.e., >6
months) with aneurysm growth of >5e10 mm.3,5e9
Several percutaneous procedures (transarterial retro-
grade embolization, translumbar sac puncture, and trans-
caval embolization) have been shown to occlude T2ELs,10e
12 although none have produced conclusive results.5,7,13
Early experience with transealing, a technique conceived
at this centre to treat T2ELs, is reported.MATERIALS AND METHODS
Patient data were prospectively collected in a dedicated
database. Included were demographic features, EVAR
operation details, transealing details, and outcomes. All
patients were given a full explanation of the procedure and
all subsequently signed a consent form.
Figure 1. (A) Pre-operative computed tomography angiography
showing the presence of a minor gap between the distal edge of
the left iliac limb and the arterial wall (arrow). (B) The remaining
limb shows good apposition to the artery wall, without type 1b
endoleak. Note. * Type 2 endoleak with feeding lumbar arteries.
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of T2ELs
This center began performing EVAR in 1994. From 1994 to
2005 all patients underwent follow-up by computed to-
mography angiography (CTA) at 1, 3, 6, and 12 months,
and yearly thereafter. From 2005 the policy was changed
to a 1-month duplex scan, a CTA at 3 months, and then
a duplex scan every 6 months with a yearly plain
abdominal radiograph. Patients with poor acoustic win-
dows also underwent an annual non-contrast CT. Control
CTA was limited to patients with persistent/suspected
endoleak.
T2ELs were deﬁned according to the reporting standards
for EVAR14 and were treated if there was diameter growth
of >5 mm. Stable endoleaks without aneurysm growth
were monitored by CTA every 6 or 12 months.
Description of the transealing technique
Landing zones in the external iliac artery were excluded
owing to the smaller caliber and risk of rupture/dissection
of this vessel during endovascular procedures. The accesssite (right or left common femoral artery) was chosen if a
minor gap between the common iliac artery and the stent-
graft could be detected on pre-operative CTA (Fig. 1). If no
gap was detected, the side with the shortest iliac limb was
used.
Percutaneous access with a 9-Fr sheath was obtained
under local anesthesia in the operating room with a
portable C-arm (OEC 9900 Elite; GE Healthcare, Salt Lake
City, UT, USA). Aortography was performed to exclude type
1/3 endoleaks.
A super-stiff guide wire (Supracore; Abbott Vascular,
Abbott Park, IL, USA) and a stiff hydrophilic wire (Terumo
Stiff; Terumo Medical, Somerset, NJ, USA) were placed in-
side the stent-graft and a Piton GC catheter (Medtronic,
Frauenfeld, Switzerland) was inserted. The stiff hydrophilic
wire was retrieved to allow the catheter to regain its cur-
vature. The introducer sheath was coaxially advanced over
the guiding catheter to offer support and to modify the
curvature of the catheter (Fig. 2). After the catheter tip was
placed against the iliac wall at the edge of the stent-graft,
the hydrophilic wire was forced between the stent-graft
and artery (Fig. 2). In some cases, progression of the wire
required the support of an angiographic catheter. The wire
was pushed deep into the sac and a 5/6-Fr introducer
sheath was advanced inside the aneurysm. Blood was suc-
tioned to verify successful entrance into the leak. If there
was no back ﬂow, a multipurpose catheter was used to
reach the nidus. Saccography was then performed to eval-
uate the leak and its feeding branches, and to exclude un-
detected type 1 endoleaks (Fig. 3).
At the discretion of the attending surgeon, coils, cyano-
acrylate, or ﬁbrin glue were deployed. When ﬁbrin glue was
used, an additional 4-Fr angiographic catheter was inserted
into the 6-Fr sheath to deliver thrombin while ﬁbrinogen
was delivered using the sheath lumen (Fig. 4).
Control saccography was then performed to assess for
the presence of lagging contrast inside the sac (Fig. 4).
Finally, the iliac limb used to access the sac was ballooned
and intra-aortic angiography was used to exclude
procedure-related type 1/3 endoleaks.Outcome assessment
Lagging contrast inside the aneurysm after control saccog-
raphy deﬁned technical success. Changes in intra-sac pres-
sure were not considered because this technique may cause
a temporary type 1b endoleak (caused by the introducer
sheath being between the iliac artery and the graft limb),
thus making it impossible to identify the origin of persistent
high pressure.
In-hospital/30-day complications were registered
(including systemic complications, access site complications,
doubling of serum creatinine, bowel ischemia and lumbar
pain, incidence of new type 1e3 endoleaks, and iliac artery
rupture/dissection).
Clinical success was deﬁned as resolution of endoleak at
follow-up associated with shrinkage or stabilization of the
sac diameter.6,7 Persistent T2ELs were monitored and re-
Figure 2. (A) Schematic depiction of the insertion of the guide wire between the stent-graft and iliac wall, with magniﬁed schematic
depiction of the Piton GC catheter (lower left corner) and ﬂuoroscopic image (upper left corner). (B) Fluoroscopic image showing the guide
wire (yellow arrow) advancing between the iliac limb and the artery wall. Note. * Introducer sheath; þ Piton GC catheter after initial
insertion;
ˇ
hydrophilic wire;  super-stiff wire.
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(sac growth 5 mm on the concomitant minor and/or
major axis at the largest aneurysm area13) and/or according
to the clinical conditions or decision of the patient.Follow-up policy
Follow-up was scheduled at 1, 3, 6, and 12 months, and
yearly thereafter. All visits included a color-coded duplex
scan, while CTA was performed at the 3-month follow-up.
Patients showing resolution of the leak at 3 months un-
derwent follow-up with duplex and/or non-contrast CT.
Patients with persistent T2ELs received CTA at 3 or 6
months in order to detect further progression. If theFigure 3. (A) Schematic depiction of the position of the introducer sheat
(B) Fluoroscopic image showing the sheath (yellow arrow) inside the sa
(lumbar arteries).diameter remained stable, follow-up continued with a 6-
month duplex scan and annual CTA.Statistical analysis
Continuous variables are presented as mean and standard
deviation/range or median and range, as appropriate.
Categorical data are reported as total counts and
percentage.
KaplaneMeier analysis was used to evaluate the rate of
freedom from treatment failure, which was deﬁned as
the composite rate of aneurysm growth þ re-
intervention þ aneurysm-related death.h between the stent-graft and aortic wall, inside the aneurysm sac.
c. (C) Saccography showing the leak nidus with two feeding vessels
Figure 4. (A) Schematic depiction of embolization with coils and ﬁbrin glue. The additional angiographic catheter used to deliver thrombin
is necessary to avoid mixing of thrombin and ﬁbrinogen inside the sheath with consequent sheath occlusion. (B) Contrast lagging inside the
aneurysm sac at the end of the procedure indicates obliteration of the leak.
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leak according to the liquid sealant used (ﬁbrin glue vs.
cyanoacrylate) and antithrombotic medications (single an-
tiplatelet drug vs. double antiplatelet or warfarin) was
performed, and the differences between the groups
examined with contingency tables and Fisher’s exact test.
Statistical analysis was performed with GraphPad Prism
(GraphPad Software, La Jolla, CA, USA); the level of signiﬁ-
cance was set at a two-tailed p-value of <.05.RESULTS
From January 1994 to April 2013, 1,559 EVARs were per-
formed at our Institution. Fifty-one patients were treated
for a T2EL. Seven patients underwent the index EVAR at a
different institution, thus leaving 44 known patients (2.8%)
treated for a T2EL. Up to December 2008, 11 patients were
treated with sac plication and ligation of feeding arteries, 10
with transfemoral embolization, nine with open conversion,
and ﬁve with endoscopic clipping of the inferior mesenteric
artery (IMA).
Between February 2009 and April 2013, 17 patients were
treated with the transealing procedure (15 men, mean age
75.6  6.8 years). The group included two patients that
underwent index EVAR at another institution. Only one
patient had been subject to a previous treatment attempt
of the T2EL (laparoscopic ligation of the IMA). All patients
were considered poor candidates for transarterialembolization (13/17 had two or more lumbar arteries
involved, and 4/17 had a patent IMA with a small diameter
or extremely tortuous Riolan arc on pre-operative CTA).5
Patient demographic data, endoleak characteristics, and
details of the index EVAR are summarized in Table 1.
Mean time from EVAR was 50.0 months (range 1e112
months). Mean aneurysm diameter at EVAR was
52.9  4.9 mm; at transealing it was 64.4  12.5 mm.
Technical success was obtained in 16/17 (94.1%) pa-
tients. The sac could not be accessed in one patient. A gap
between the iliac limb and the artery wall was detected in
13 (76.0%) patients at pre-operative CTA and was used to
access the aneurysm sac.
Median values were 90 minutes (range 65e192 minutes)
and 18 minutes (range 7e48 minutes) for procedural time
and ﬂuoroscopy time, respectively. Fibrin glue alone (Tis-
sucol; Baxter, Vienna, Austria) was used in 1/16 (6.2%)
successful cases; ﬁbrin glue and coils (Tornado/Nester 0.035
inche8.000 mm coiled embolus diameter; Cook, Bjaever-
skov, Denmark) were used in nine (56.3%) cases; cyanoac-
rylate glue (Glubran; GEM, Viareggio, Italy) plus ethiodized
oil (Lipiodol; Guerber Group, Paris, France) and coils were
used in ﬁve cases (31.3%); and cyanoacrylate and ethiodized
oil alone were used in one case (6.2%).
In three (17.6%) cases, transealing was associated with
supplementary endovascular procedures. One patient had
concomitant embolization of a hypogastric aneurysm; one
patient had an iliac extension because of a short (<10 mm)
Table 1. Patient demographic data, details of the index
endovascular aortic aneurysm repair (EVAR) operation, and
characteristics of the type 2 endoleak (T2EL).
Variable Mean  SD
or n (%)
Age, y 75.6  6.8
Male 15/17 (88.2)
CAD 7/17 (41.2)
Smoking habit 8/17 (47.1)
Hyperlipidemia 10/17 (588)
Hypertension 16/17 (94.1)
Diabetes mellitus 2/17 (11.8)
COPD 4/17 (23.5)
Cerebrovascular accidents 2/17 (11.8)
Chronic kidney failure 2/17 (11.8)
Mean blood creatinine at
admission, mg/dL
1.1  0.2
Antithrombotic therapy 17/17 (100.0)
Single antiplatelet 13/17 (76.5)
Double antiplatelet 1/17 (5.9)
Anticoagulant 3/17 (17.6)
ASA class 3e4 patients 15/17 (88.2)
Time from index EVAR, mo 50.0  33.6
Mean aneurysm diameter at index
EVAR, mm
52.9  4.9
Bifurcated stent-graft 16/17 (94.1)
Type of stent-graft
Endologix Powerlink 5/17 (29.4)
Gore Excluder 4/17 (23.5)
Cook Zenith 4/17 (23.5)
Medtronic Talent 2/17 (11.8)
Cordis Teramed 1/17 (5.9)
Medtronic AneuRx 1/17 (5.9)
Mean aneurysm diameter at
transealing, mm
64.4  12.5
Mean increase in sac diameter 12.9  8.4 mm
Indication for treatment
Persistent T2EL with greater
than 5 mm aneurysm growth
16/17 (94.1)
T2EL in a previously symptomatic
aneurysm
1/17 (5.9)
Preoperative CTA characteristics
Patent IMA 4/17 (23.5)
Patent lumbar arteries 6/17 (35.3)
Patent IMA and lumbar arteries 7/17 (41.2)
Mean number of feeding arteries 2.4  1.1
Note. CAD ¼ coronary artery disease; COPD ¼ chronic obstructive
pulmonary disease; ASA ¼ American Society of Anesthesiologists;
CTA ¼ computed tomography angiography; IMA ¼ inferior
mesenteric artery.
Table 2. Operative data and results of the transealing procedure.
Variable Mean  SD,
median (range)
or total n (%)
Local anesthesia 16/17 (94.1)
Right femoral access 14/17 (82.3)
Procedural time, mins (median) 90 (69e92)
Procedural time, mins (mean) 107  43
Fluoroscopy time, mins (median) 18 (7e48)
Contrast volume, cc 194.8  60.8
Immediate technical success 16/17 (94.1)
Reason for technical failure
Impossible to access the sac 1/1 (100)
Other 0/1 (0)
Type of sealant used
Fibrin glue 1/16 (6.2)
Fibrin glue and coils 9/16 (56.3)
Cyanoacrylate glue þ ethiodized oil 1/16 (6.2)
Cyanoacrylate glue þ ethiodized
oil and coils
5/16 (31.3)
Number of coils per patient (median) 3 (2e5)
Additional endovascular procedures 3/17 (17.6)
Embolization of hypogastric aneurysm 1/17 (5.9)
Iliac extension for short iliac limb 1/17 (5.9)
Iliac extension for secondary type
1b endoleak
1/17 (5.9)
Other 0/17 (0.0)
In-hospital stay, d (median) 5 (3e52)
Perioperative complications
Death 0/17 (0.0)
Visceral embolization 1/17 (5.9)
Lumbar pain 1/17 (5.9)
Transient serum creatinine elevation 1/17 (5.9)
Iliac artery rupture/dissection 0 (0.0)
Mean material costs, Va 1,359.7  510.4
a Mean material costs included the iliac extension used to treat
the secondary type 1b endoleak.
398 G. Coppi et al.overlap of the contralateral iliac limb within the common
iliac artery (both procedures were planned and not com-
plications of transealing).
In one (5.9%) case, an iliac extension was inserted for a
type 1b endoleak secondary to the transealing procedure.
Type 1a/3 endoleaks and iliac artery ruptures/dissections
did not occur.
There was one (5.9%) major complication. A patient
treated with acrylic surgical glue and coils suffered from
colon ischemia caused by embolization through the IMA.This patient underwent surgical resection of the necrotic
segment and was discharged after 52 days without per-
manent stoma. The patient is alive and well 8 months
following surgery.
Other minor complications included one (5.9%) case of
transient lumbar pain requiring intravenous non-steroidal
anti-inﬂammatory drugs (this patient was also treated
with cyanoacrylate) and one (5.9%) case of transient
creatinine elevation that resolved at discharge. Operative
data and results are summarized in Table 2.
Mean follow-up was 21.5 months (range 1.0e42.0
months). One patient was lost to follow-up at 2 months. 3-
month follow-up was therefore completed in 15 (88.2%)
patients, with resolution of the endoleak in 8/15 (53.0%)
patients. At 1 year, complete resolution was present in 5/11
(45.5%) patients, while in three (27.2%) patients the
endoleak was still detectable, but the aneurysm diameter
had not increased.
There were three (18.8%) cases of treatment failure in
the group of 16 patients judged to have had a technically
successful procedure. One (6.2%) case of persistent T2EL
with sac enlargement was treated by re-do transealing and
Figure 5. KaplaneMeier analysis of overall rate of treatment fail-
ure (continuous line) and according to the absence or presence of
type 2 endoleak (T2EL) at 3 months (dotted lines). Time is
expressed in months. Note. SEM ¼ standard error of the mean.
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of the leak. One (6.2%) patient with persistent T2EL un-
derwent conversion at 33 months for a symptomatic
aneurysm with a diameter of 92 mm (the diameter at
transealing was 86 mm). One (5.3%) patient presented
with a persistent T2EL with aneurysm enlargement
(7 mm), but refused treatment owing to concomitant
metastatic cancer.
In this group, freedom from treatment failure was
therefore 90.0% at 1 year. The rate reduced to 77.1% and to
51.4% for patients who were monitored up to 2 and 3 years,
respectively. Treatment failure occurred only in patients
with persistent T2EL at 3 months, although the difference
did not reach statistical signiﬁcance (p ¼ .19) (Fig. 5).
There was no signiﬁcant association between the inci-
dence of persistent T2EL at 3 months and the liquid sealant
used, that is, ﬁbrin glue versus cyanoacrylate (odds ratio
[OR] 1.6; 95% conﬁdence interval [CI] 0.2e14.2; p ¼ .1).
Similarly, there was no signiﬁcant difference in the rate of
persistent T2EL at 3 months and the antithrombotic therapy
used, that is, single antiplatelet versus double antiplatelet/
warfarin (OR 0.7; 95% CI 0.1e6.9; p ¼ .1).DISCUSSION
These preliminary results show that transealing is feasible,
with a high immediate technical success (94.1%), which is in
line with other percutaneous techniques (transarterial
retrograde embolization: 65.0e100.0%16,17; translumbar
sac puncture: 90.0e100.0%4,13,15,17; transcaval emboliza-
tion: 92.0e100.012,18). Compared to the aforementioned
techniques, transealing has both similarities and
differences.
Like the translumbar and transcaval techniques, trans-
ealing is based on direct sac embolization. Sac embolization
is considered by several authors4,17,19 to favor occlusion
because, in association with liquid sealants, it allows the
obliteration of more leak components (inﬂow vessels, nidus,
outﬂow vessels).5,13,15,19,20The main difference, and advantage, of the transealing
procedure is its ease of use.
Transealing does not require knowledge of micro-
catheters, as used in transfemoral embolization,16 nor of
the transjugular liver access systems needed for transcaval
treatment.12,18 All the cases in this study were performed
without the advanced imaging tools (cone-beam CT, rota-
tional angiography) often used in translumbar emboliza-
tion.4,15 Unlike translumbar embolization, transealing does
not need conscious sedation nor does it require the patient
to be in a prone position,4,15 which, for the elderly, can be
uncomfortable. Moreover, the supine position allows
collateral endovascular treatments to be performed18
(three of the patients in this study underwent additional
procedures).
This procedure is also cost-effective, as the procedural
time was quite brief and the mean cost of the endovascular
materials was V1,359.70, approximately V250 less than the
cost of transfemoral embolization at this institution.
There were two main complications: one case of colon
ischemia and one case of secondary endoleak.
Colon ischemia during T2EL treatment is directly related
to the use of liquid sealants,13 and has been described
with both the transfemoral and translumbar
approach.21,22 Liquid sealants have a greater occlusion
rate than coils alone, possibly because of the tendency to
spread and occlude more leak components, but this in-
creases the risk of spilling into unwanted areas (colon,
lumbar plexus).13
In this study, ﬁbrin glue had a better safety proﬁle than
cyanoacrylate (both colon ischemia and transient lumbar
pain occurred with the latter), even though it’s correct
deployment needed a technical expedient to avoid sheath
thrombosis (Fig. 4). As the incidence of persistent T2EL was
the same between the two sealants, the use of cyanoac-
rylate has been abandoned.
Instead, the development of a secondary type 1b
endoleak was speciﬁc to transealing. Even though the leak
was successfully treated without complications, this risk
represents the main drawback of the technique. No type
1a/3 endoleaks were detected, which possibly implies
that any risk of graft mobilization is limited to the iliac
level.
In the future, the use of smaller and more ﬂexible
sheaths might reduce the incidence of secondary leaks,
although it should be noted that this complication has also
been reported with translumbar embolization (type 3 leak
due to stent-graft perforation).15
Mid-term results need further improvement. The rate of
persistent leaks was 55.0% at 12 months, and the rate of
failure reached 48.6% at 3 years. These results, though far
from satisfying, are in line with those of other percutaneous
techniques. Aziz et al.7 assessed a cohort of 42 patients
treated mainly by translumbar embolization, and concluded
that treatment does not alter the rate of aneurysm growth.
Similarly, Abularrage et al.23 reported that intervention for
T2EL was associated with success in less than a half of cases
in a group of 51 patients. In an important retrospective
400 G. Coppi et al.analysis of 95 patients treated mainly with transarterial
embolization, Sarac et al.13 reported a rate of 44.0%
freedom from sac expansion of >5 mm at 3 years, which is
comparable to the freedom-from-failure rate in this study
(all failures in this study had an aneurysm growth of
>5 mm).
One possible reason for the high rate of persistent leaks
is that, owing to the technique being in its infancy, more
caution was exercised, with the use of small coils, and, most
importantly, reduced quantities of glue. Increasing the
amount of glue or employing newer sealants, such as
ethylene vinyl alcohol copolymer,23 might, in the future,
improve the occlusion rate.
CONCLUSION
Although the possibility of a retrograde peri-graft sac access
from the iliac artery has also been reported by Massis
et al.,24 this study represents the ﬁrst complete description
of the technique, with analysis of its outcomes.
Regarding the latter, transealing was found to have a
technical success rate comparable with other percutaneous
treatments, with similar mid-term results.
In conclusion, this study shows that the transealing
technique is feasible and safe, and represents a valid
alternative in selected patients with T2ELs. Its advantages
are mainly its low invasiveness, low costs, and ease of use.
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